Document Detail


Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study.
MedLine Citation:
PMID:  22278628     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Azilsartan is a novel angiotensin receptor blocker being developed for hypertension treatment. This 16-week, multicenter, randomized, double-blind study compared the efficacy and safety of azilsartan (20-40 mg once daily by forced titration) and its ability to provide 24-h blood pressure (BP) control, with that of candesartan cilexetil (candesartan; 8-12 mg once daily by forced titration) in 622 Japanese patients with grade I-II essential hypertension. Efficacy was evaluated by clinic-measured sitting BP, and by ambulatory BP monitoring (ABPM) at week 14. Participants (mean age: 57 years, 61% males) had a mean baseline sitting BP of 159.8/100.4 mm Hg. The mean change from baseline in sitting diastolic BP at week 16 (primary endpoint) was -12.4 mm Hg in the azilsartan group and -9.8 mm Hg in the candesartan group, demonstrating a statistically significant greater reduction with azilsartan vs. candesartan (difference: -2.6 mm Hg, 95% confidence interval (CI): -4.08 to -1.22 mm Hg, P=0.0003). The week 16 (secondary endpoint) mean change from baseline in sitting systolic BP was -21.8 mm Hg and -17.5 mm Hg, respectively, a significant decrease with azilsartan vs. candesartan (difference: -4.4 mm Hg, 95% CI: -6.53 to -2.20 mm Hg, P<0.0001). On ABPM, the week 14 mean changes from baseline in diastolic and systolic BP were also significantly greater with azilsartan over a 24-h period, and during the daytime, night-time and early morning. Safety and tolerability were similar among the two groups. These data demonstrate that once-daily azilsartan provides a more potent 24-h sustained antihypertensive effect than that of candesartan but with equivalent safety.
Authors:
Hiromi Rakugi; Kazuaki Enya; Kenkichi Sugiura; Yoshinori Ikeda
Related Documents :
1248998 - Comparative evaluation of pressure and time factors in estimating left ventricular perf...
22872368 - Influence of end-expiratory level and tidal volume on gravitational ventilation distrib...
22703478 - Effect of carvedilol and nebivolol on oxidative stress-related parameters and endotheli...
2452918 - Short-term assessment of left ventricular function, coronary hemodynamics, and catechol...
24761938 - Hemodynamic changes in child acute respiratory distress syndrome with airway pressure r...
15884778 - Reference cardiopulmonary values in normal dogs.
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2012-01-26
Journal Detail:
Title:  Hypertension research : official journal of the Japanese Society of Hypertension     Volume:  35     ISSN:  1348-4214     ISO Abbreviation:  Hypertens. Res.     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-05-07     Completed Date:  2012-09-11     Revised Date:  2013-06-26    
Medline Journal Info:
Nlm Unique ID:  9307690     Medline TA:  Hypertens Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  552-8     Citation Subset:  IM    
Affiliation:
Department of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine, Osaka, Japan. rakugi@geriat.med.osaka-u-ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Angiotensin Receptor Antagonists / adverse effects,  therapeutic use*
Antihypertensive Agents / adverse effects,  therapeutic use*
Asian Continental Ancestry Group
Benzimidazoles / adverse effects,  therapeutic use*
Biphenyl Compounds / adverse effects,  therapeutic use*
Double-Blind Method
Female
Humans
Hypertension / drug therapy*
Male
Middle Aged
Oxadiazoles / adverse effects,  therapeutic use*
Severity of Illness Index
Tetrazoles / adverse effects,  therapeutic use*
Chemical
Reg. No./Substance:
0/Angiotensin Receptor Antagonists; 0/Antihypertensive Agents; 0/Benzimidazoles; 0/Biphenyl Compounds; 0/Oxadiazoles; 0/Tetrazoles; F9NUX55P23/azilsartan; R85M2X0D68/candesartan cilexetil
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Daily dialysis reduces pulse wave velocity in chronic hemodialysis patients.
Next Document:  Protective Effect of Puerarin on ?-Amyloid-Induced Neurotoxicity in Rat Hippocampal Neurons.